Trinity Capital, an alternative asset manager, committed $45 million in growth capital to Rapid Micro Biosystems, a life sciences technology company providing automation solutions to facilitate the manufacturing and release of healthcare products.
“In an industry where quality cannot be compromised, Rapid Micro Biosystems is delivering the automation and dependability manufacturers need,” Rob Lake, senior managing director of life sciences at Trinity Capital, said. “They are transforming a critical process within biopharma manufacturing, and we are proud to partner with a team driving meaningful impact across the industry.”
This new capital will help scale Rapid Micro’s operations, to include supporting the continued global commercial expansion of the Growth Direct platform and ongoing investments to drive gross margin expansion.
“We are pleased to partner with Trinity Capital, who shares our vision of automating manual microbial quality control testing methods used in biopharma manufacturing,” Robert Spignesi, president and CEO of Rapid Micro Biosystems, said. “This facility significantly strengthens our financial position and supports our continued focus on long-term revenue growth, margin expansion, and increasing shareholder value.”
